Novartis Ag

Medarex Inc.

Bioseek, Inc.

Medisup International, N.v.

Laboratoire European De Biotechnologie S.a.

Discoverrx Corporation

Asterand Acquisition LLC

Ivan Plavec

Michael Kaleko

Tianci Luo

Michael Gerard Tovey

Patrick Benoit

Francois Meyer

Janet Lynn Douglas

Eugene C Butcher

Ellen L Berg

Deborah Maguire

Debborah Maguire

Jennifer Melrose

Eric J Kunkel

Gabor Veres

Evangelos Hytopoulos

Manju Agarwal

Agents that inhibit or prevent restenosis are identified by assaying test agents in a battery of assays to measure the effect of the test agent on cell proliferation, thrombosis, tissue modeling, and inflammation. Treatment for restenosis is provided using compositions of the invention.

Methods for identifying agents and their use for the prevention of restenosis

The present invention provides novel lentiviral packaging constructs that are useful for the establishment of stable packaging cell lines and producer cell lines. In particular, the present invention provides novel packaging cell lines that are capable of constitutively expressing high levels of lentiviral proteins.

Lentiviral packaging constructs

A method of screening biologically active agent based on the analysis of complex biological responses in culture. Methods for selecting cells and culture conditions for such screens are provided, as well as the identification of an optimized set of discrete parameters to be measured, and the use of biomap analysis for rapid identification and characterization of drug candidates, genetic sequences acting pathways, and the like. A feature of the invention is simultaneous screening of a large number of cellular pathways, and the rapid identification of compounds that cause cellular responses.

Function homology screening

The invention relates to a monoclonal antibody directed against the human interferon class I receptor (IFN-R) characterized by the following properties: it recognizes the extracellular domain of the human IFN-R, and it has a neutralizing capacity against the biological properties of the human type I-IFN. It further concerns their use for the diagnosis.

Monoclonal antibodies against the interferon receptor, with neutralizing activity against type I interferon

The involvement of an expression product in a cell in a pathway is determined by genetically modifying the cell, incubating the cell with predetermined factors in induce a physiological state and measuring parameters affected by the pathway. Changes in the levels of the parameters as a result of the presence of the expressed product indicate that the expression product is involved with the pathway.

BioMAP analysis

Monoclonal antibodies against the interferon receptor, with neutralizing activity against type 1 interferon

A monoclonal antibody is provided which is directed against the human interferon type I receptor (IFN-R), which recognizes the extracellular domain of the human IFN-R and which has neutralizing capacity against the biological properties of human type I-IFN. Diagnostic and therapeutic applications for the monoclonal antibody also are provided.

Isolated peptide or polypeptide of the extracellular portion of the human interferon receptor (IFN-R).

This invention relates to a method of using scaffold attachment regions (SARs) to increase expression in retrovirally transduced resting cells. A particularly preferred SAR is the 5&prime; SAR of the human interferon &bgr; gene or a fragment thereof having at least 450 base pairs.

Vectors comprising SAR elements

Monoclonal antibodies against the interferon receptor, with neutralizing

Growing community of inventors

Sunnyvale, CA, United States of America

Ivan Plavec